Mantle Cell Lymphoma Guidelines Let Some Patients Skip Transplant

Updated national treatment guidelines for mantle cell lymphoma (MCL) lean more on targeted pills and, for some people, drop the need for a stem cell transplant after first treatment. The National Comprehensive Cancer Network (NCCN) published Version 4.2026 of its B-cell lymphoma guidelines in the September 2026 issue of the Journal of the National Comprehensive Cancer Network, posted online Sept. 16, 2026.

MCL is an uncommon type of non-Hodgkin lymphoma. NCCN guidelines are what many cancer doctors across the U.S. use to choose treatment, and insurers often look to them when deciding what to cover.

What Changed for People Starting Treatment

For people healthy enough for intensive treatment, and whose lymphoma does not have a change in the TP53 gene, the guidelines list the TRIANGLE regimen as a preferred first treatment. It combines chemotherapy and the antibody rituximab with a BTK inhibitor, a daily pill that blocks a protein lymphoma cells need to grow, followed by maintenance treatment. It is named for the phase 3 TRIANGLE trial, which added Imbruvica (ibrutinib) to standard treatment. The guidelines allow the newer BTK inhibitors Calquence (acalabrutinib) or Brukinsa (zanubrutinib) in its place, although neither was tested in that trial.

For people who are older or can't handle intensive treatment, the preferred options are Calquence plus bendamustine and rituximab (a combination called BR), Calquence plus rituximab, or BR alone. The FDA approved Calquence with BR for previously untreated MCL in January 2025, as CURE reported at the time.

Who May Be Able to Skip a Stem Cell Transplant

For years, many younger, fit patients received high-dose chemotherapy followed by an autologous stem cell transplant, which uses their own stem cells, after their first treatment. The updated guidelines say the role of this step is lessening.

The decision now leans on a test for minimal residual disease (MRD): tiny amounts of lymphoma left in the body that scans can't see. The guidelines call for a very sensitive MRD test after first treatment, one able to find a single lymphoma cell among a million normal cells.

• Complete response and no detectable MRD: no transplant. Patients move on to rituximab maintenance, with or without a BTK inhibitor.
• Complete response but MRD still detectable: a transplant remains an option, followed by maintenance.

This approach is supported by the phase 3 EA4151 trial, presented in December 2024 at the American Society of Hematology annual meeting. Among 516 people in complete remission with no detectable MRD, 82.1% of those who had a transplant plus rituximab maintenance were alive after three years, compared with 82.7% of those who had rituximab maintenance alone. Read CURE's earlier coverage of that trial.

If Your MCL Has a TP53 Mutation

Changes in the TP53 gene are linked to MCL that grows faster and responds less well to standard treatment. The guidelines list TP53 gene testing as essential at diagnosis. For people with a TP53 mutation, the panel strongly recommends a clinical trial. Outside a trial, options include a combination of venetoclax, zanubrutinib and obinutuzumab, the TRIANGLE regimen for people who can handle intensive treatment, or Calquence plus rituximab for those who can't.

Side Effects to Know

BTK inhibitors can cause bruising or bleeding, an irregular heartbeat called atrial fibrillation, high blood pressure, diarrhea and infections. The guidelines note that taking a BTK inhibitor continuously along with rituximab maintenance raises the risk of serious infections, so your team may watch closely for them and talk with you about vaccines and when to call.

What's Still Unknown

• Calquence and Brukinsa have not been tested in the TRIANGLE regimen itself; the panel allows them based on how similar the drugs are.
• Patients in EA4151 were followed for a median of 2.7 years, and longer-term results are still coming.
• Guidelines are recommendations. The right plan for you depends on your age, overall health, the features of your lymphoma and your own preferences.

What It Means for You

If you are starting treatment for MCL, a targeted pill is likely to be part of your plan from the beginning. And if your first treatment clears the lymphoma down to undetectable levels, you may be able to avoid a transplant and the weeks of recovery that come with it.

Questions to Ask Your Care Team

• Has my lymphoma been tested for a TP53 mutation, and what did it show?
• Which first treatment do you recommend for me, and does it include a BTK inhibitor?
• Will I have an MRD test after treatment, and how sensitive is it?
• If my MRD is undetectable, do I still need a stem cell transplant?

References

1. "B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines in Oncology." Zelenetz AD, et al. Journal of the National Comprehensive Cancer Network. Sept. 16, 2026.
2. "Autologous Stem Cell Transplants Do Not Improve Survival for Mantle Cell Lymphoma Patients With Undetectable MRD, Clinical Trial Shows." ECOG-ACRIN Cancer Research Group. Dec. 10, 2024.
3. "FDA Approves Acalabrutinib With Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma." U.S. Food and Drug Administration. Jan. 16, 2025.
4. "Ibrutinib Combined With Immunochemotherapy With or Without Autologous Stem-Cell Transplantation as First-Line Treatment for Patients With Mantle Cell Lymphoma (TRIANGLE)." Dreyling M, et al. The Lancet. May 2024